title: Cost implications of new treatments for advanced colorectal cancer.
abstract: BACKGROUND
  Since 1996, 6 new drugs have been introduced for the treatment of metastatic colorectal cancer. Although they are promising, these drugs frequently are given in the palliative and are much more expensive than older treatments. The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies.
  
  
  METHODS
  A Markov model was used to evaluate a hypothetical cohort of 1000 patients with newly diagnosed, metastatic colorectal cancer. Patients supposedly received up to 3 lines of treatment before supportive care and subsequent death. Data were obtained from published, multicenter phase 2 and randomized phase 3 clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity, and cost.
  
  
  RESULTS
  Using drug costs alone, treatment that included new chemotherapeutic agents increased survival at an incremental cost-effectiveness ratio (ICER) of $100,000 per discounted life-year (DLY). The addition of monoclonal antibodies improved survival at an ICER of >$170,000 per DLY. The results were most sensitive to changes in the initial regimen. Even with significant improvements in clinical characteristics (efficacy and toxicity), treatment with the most effective regimens still had very high ICERs.
  
  
  CONCLUSIONS
  Treatment of metastatic colorectal cancer with the most effective regimens came at very high incremental costs. The authors concluded that cost-effectiveness analyses should be a routine component of the drug-development process, so that physicians and patients are informed appropriately regarding the value of new innovations.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. y_wong@fccc.edu
authors.forename: Yu-Ning
authors.initials: YN
authors.lastname: Wong
authors.forename: Neal J
authors.initials: NJ
authors.lastname: Meropol
authors.forename: William
authors.initials: W
authors.lastname: Speier
authors.forename: Daniel
authors.initials: D
authors.lastname: Sargent
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
authors.forename: J Robert
authors.initials: JR
authors.lastname: Beck
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000473:pathology; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009010:Monte Carlo Method; D009362:Neoplasm Metastasis
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents